1. Classification and Chemical Overview

Armodafinil (marketed under brand names such as Nuvigil) is a wakefulness-promoting agent classified under the Anatomical Therapeutic Chemical (ATC) code N06BA13.

Chemically designated as 2-[(R)-(diphenylmethyl)sulfinyl]acetamide, armodafinil is the isolated enantiomer composed exclusively of the active ($R$)-enantiomer of racemic modafinil. In clinical practice, the 150 mg strength represents the standard therapeutic single daily oral dose for most adult indications. It is classified as a Controlled Substance (Schedule IV under US federal regulations) and as a Prescription Only Medicine (POM) across international jurisdictions due to low-to-moderate potential for abuse and dependence relative to classic amphetamine-like stimulants.

2. Mechanism of Action and Pharmacodynamics

Armodafinil differs structurally and pharmacologically from classical sympathomimetic central nervous system stimulants (such as amphetamines or methylphenidate). It does not act directly as an agonist at peripheral adrenergic receptors or induce significant non-specific monoamine release.

The primary mechanism of action involves competitive binding to the dopamine transporter (DAT), inhibiting dopamine reuptake and increasing extracellular dopamine levels in specific brain regions, particularly the striatum, nucleus accumbens, and hypothalamus. Additionally, armodafinil indirect modulates orexin/hypocretin, histamine, and gamma-aminobutyric acid (GABA) neuronal pathways in the anterior hypothalamus, producing selective cortical arousal and wakefulness without widespread sympathomimetic activation.

3. Approved Clinical Indications and Therapeutic Scope

Regulatory approvals for oral armodafinil 150 mg include:

• Narcolepsy: Management of excessive daytime sleepiness (EDS) in adult patients with narcolepsy (150 mg or 250 mg taken once daily in the morning).

• Obstructive Sleep Apnea (OSA): Adjunctive therapy to reduce excessive sleepiness in adult patients receiving optimal continuous positive airway pressure (CPAP) treatment for OSA (150 mg or 250 mg taken once daily in the morning).

• Shift Work Disorder (SWD): Management of excessive sleepiness associated with chronic shift work disorder (150 mg taken approximately 1 hour prior to the start of the work shift).

Dosing Considerations: A single 150 mg tablet daily provides therapeutic systemic exposure throughout the active wake period due to the longer elimination half-life of the ($R$)-enantiomer compared to racemic modafinil. Lower initial doses (e.g., 50 mg to 75 mg) are recommended in elderly patients or patients with severe hepatic impairment.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Armodafinil is rapidly absorbed following oral administration. Peak plasma concentration (Tmax​) is reached within 2 hours post-dose in the fasted state. Absolute bioavailability is high, and food delays Tmax​ by approximately 2 to 4 hours without significantly altering overall area under the curve ($\text{AUC}$).

• Distribution: Armodafinil exhibits a moderate volume of distribution (Vd​≈0.6 L/kg). It is bound approximately 60% to plasma proteins, predominantly to human serum albumin.

• Biotransformation: Armodafinil is extensively metabolised by hepatic Phase I and Phase II pathways. The primary route involves hydrolytic amide cleavage to armodafinil acid (inactive). A secondary pathway involves Phase I oxidation mediated by Cytochrome P450 3A4/5 (CYP3A4/5) to form modafinil sulfone.

• Elimination: Eliminates via renal excretion of metabolites (< 10% excreted as unchanged drug). The elimination half-life (t1/2​) is approximately 12 to 15 hours, maintaining plasma concentrations suitable for sustained once-daily dosing.

5. Physiological Effects and Adverse Event Spectrum

Armodafinil increases central cortical alertness, motor activity, and cognitive vigilance while causing minimal systemic cardiovascular activation compared to traditional stimulants.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Headache.

• Common ($\ge 1/100$ to $<1/10$): Nausea, insomnia, dizziness, dry mouth, anxiety, dyspepsia, diarrhoea, fatigue, palpitations, irritability, rash.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Anorexia, depression, agitation, tremor, paraesthesia, dyspnoea, hypertension, tachycardia, hyperhidrosis, muscle spasms, urinary disturbance.

• Rare / Serious (<1/1,000): Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); psychiatric reactions (psychosis, mania, suicidal ideation); hypersensitivity reactions.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindications

• Known hypersensitivity to armodafinil, modafinil, or formulation excipients.

• History of left ventricular hypertrophy or mitral valve prolapse associated with CNS stimulant use.

Key Drug Interactions

• Hormonal Contraceptives: Armodafinil is a moderate inducer of CYP3A4. Concomitant use significantly reduces plasma levels of hormonal contraceptives (oral, transdermal, implantable), leading to contraceptive failure. Alternative or non-hormonal contraception must be maintained during treatment and for one month following discontinuation.

• CYP3A4 Substrates: Co-administration reduces systemic exposure of drugs metabolised by CYP3A4 (e.g., cyclosporine, triazolam, midazolam, statins).

• CYP2C19 Inhibitors/Substrates: Armodafinil mildly inhibits CYP2C19, increasing plasma concentrations of co-administered substrates (e.g., omeprazole, diazepam, phenytoin, $S$-mephenytoin).

• Warfarin: Regular monitoring of prothrombin time/INR is recommended when co-administering with warfarin due to potential CYP-mediated metabolic alterations.

Clinical Precautions and Monitoring

• Cutaneous Reactions: Armodafinil must be discontinued immediately at the first sign of a rash or mucosal lesion, as serious life-threatening dermatological reactions (SJS/TEN) cannot be reliably predicted.

• Psychiatric Monitoring: Patients should be monitored for the emergence or worsening of psychiatric symptoms, including severe anxiety, agitation, mania, hallucination, or suicidal ideation.

• Cardiovascular Status: Blood pressure and heart rate should be routinely monitored, particularly in patients with pre-existing cardiovascular conditions or underlying hypertension.